Author

Guoda Daukėlaitė

Observed name: Guoda Daukelaite

Institutions: Vilnius University, Vilnius University Hospital Santariskiu Klinikos

Observed institutions: Tel Aviv University, Vilnius University, Homi Bhabha National Institute, Medical University of Warsaw, Tata Memorial Hospital, Rabin Medical Center, The Alfred Hospital, Advanced Centre for Treatment, Research and Education in Cancer, Vilnius University Hospital Santariskiu Klinikos, Szpital Uniwersytecki w Krakowie, Weill Cornell Medicine

OpenAlex ID: A5034255404

Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients

2021 · Andrius Zucenka, Kazimieras Maneikis, et al. · Annals of Hematology · 14

PDF

Immunogenicity and clinical effectiveness of mRNA vaccine booster against SARS‐CoV ‐2 Omicron in patients with haematological malignancies: A national prospective cohort study

2023 · Lukas Kevličius, Karolis Šablauskas, et al. · British Journal of Haematology · 8

Hypomethylating agents or chemotherapy in combination with venetoclax and gilteritinib for FLT3-mutated Acute Myeloid Leukemia

2025 · Andrius Zucenka, Milda Mikalonyte, et al. · Blood · 1

PDF

Individualized Sequential Allogeneic Stem Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Patients with Active Disease

2024 · Andrius Zucenka, Lukas Kevličius, et al. · Blood · 1

ORAL ABSTRACT: AML-1299: Actinomycin D in Combination With Low-Dose Cytarabine and Venetoclax in Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

2026 · Tautvilė Smalinskaitė, Milvydė Tamutytė-Jankauskė, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: AML-998: Outcomes of Consolidative Allogeneic Transplantation After Venetoclax Plus Hypomethylating Agent Induction in Acute Myeloid Leukemia: A Single-Center Retrospective Study

2026 · Milvydė Tamutytė-Jankauskė, Milda Mikalonytė, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: AML-783: Upfront Allogeneic Stem Cell Transplantation With Individualized Venetoclax-Based Conditioning in MECOM-Rearranged Acute Myeloid Leukemia: A Single-Center Retrospective Study

2026 · Milda Mikalonytė, Milvydė Tamutytė-Jankauskė, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: AML-1299: Actinomycin D in Combination With Low-Dose Cytarabine and Venetoclax in Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

2026 · Tautvilė Smalinskaitė, Milvydė Tamutytė-Jankauskė, et al. · Clinical Lymphoma Myeloma & Leukemia

Conditioning with alkylating agents, cytarabine, cladribine, hypomethylating agents, and venetoclax (ARCHIVE) for upfront allogeneic stem cell transplantation in patients with active Acute Myeloid Leukemia or myelodysplastic syndrome with increased blasts-2

2025 · Andrius Zucenka, Lukas Kevlicius, et al. · Blood

POSTER: MM-721 Selinexor-Based Therapy for Patients With Relapsed/Refractory Multiple Myeloma

2025 · Guoda Daukėlaitė, L Davainis, et al. · Clinical Lymphoma Myeloma & Leukemia

AML-535: Gilteritinib in Combination With Venetoclax, Low-Dose Cytarabine, and Actinomycin D As Salvage Therapy for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia (FLT3m R/R AML): A Single-Center Retrospective Study

2025 · Milda Mikalonyte, Tautvile Smalinskaite, et al. · Clinical Lymphoma Myeloma & Leukemia

MM-721: Selinexor-Based Therapy for Patients With Relapsed/Refractory Multiple Myeloma

2025 · Guoda Daukelaite, L Davainis, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: AML-535 Gilteritinib in Combination With Venetoclax, Low-Dose Cytarabine, and Actinomycin D As Salvage Therapy for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia (FLT3m R/R AML): A Single-Center Retrospective Study

2025 · Milda Mikalonytė, Tautvilė Smalinskaitė, et al. · Clinical Lymphoma Myeloma & Leukemia

Targeted, Low Cost Epigenetic Microarray for AML and MDS Detection

2024 · Miriam Neaman, Mika Bell, et al. · Blood

AML-672 Venetoclax-Based Preconditioning Followed by Immediate Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or High-Risk Myelodysplastic Syndromes (HR-MDS)

2024 · Lukas Kevlčius, Tautvilė Smalinskaitė, et al. · Clinical Lymphoma Myeloma & Leukemia

AML-700 Prolonged Cytopenias After First-Line Treatment With Venetoclax and Hypomethylating Agent in Newly Diagnosed AML/MDS-IB

2024 · Tautvilė Smalinskaitė, Lukas Kevličius, et al. · Clinical Lymphoma Myeloma & Leukemia

Venetoclax-Based Preconditioning Followed by Immediate Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or High-Risk Myelodysplastic Syndromes (HR-MDS)

2024 · Lukas Kevličius, Tautvilė Smalinskaitė, et al. · Clinical Lymphoma Myeloma & Leukemia

Prolonged Cytopenias After First-Line Treatment With Venetoclax and Hypomethylating Agent in Newly Diagnosed AML/MDS-IB

2024 · Tautvilė Smalinskaitė, Lukas Kevličius, et al. · Clinical Lymphoma Myeloma & Leukemia

Real-World Comparison of Venetoclax-Based Treatment Versus Intensive Chemotherapy As Bridging to Allogeneic Stem Cell Transplantation in MDS-IB2 Patients

2023 · Andrius Zucenka, Birutė Davainienė, et al. · Blood

POSTER: AML-377 Venetoclax in Combination With Low-Dose Cytarabine and/or Actinomycin D in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Patients With IDH1 or IDH2 Mutations

2023 · Guoda Daukėlaitė, Dominika Vasilevska, et al. · Clinical Lymphoma Myeloma & Leukemia

AML-377 Venetoclax in Combination With Low-Dose Cytarabine and/or Actinomycin D in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Patients With IDH1 or IDH2 Mutations

2023 · Guoda Daukėlaitė, Dominika Vasilevska, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: AML-519 Sequential Allogeneic Stem Cell Transplantation (alloSCT) After Venetoclax (Ven)-Based Therapy for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Myelodysplastic Syndrome With Excess Blasts 2 (MDS-EB2)

2023 · Dominika Vasilevska, Guoda Daukėlaitė, et al. · Clinical Lymphoma Myeloma & Leukemia

PDF

AML-519 Sequential Allogeneic Stem Cell Transplantation (alloSCT) After Venetoclax (Ven)-Based Therapy for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Myelodysplastic Syndrome With Excess Blasts 2 (MDS-EB2)

2023 · Dominika Vasilevska, Guoda Daukėlaitė, et al. · Clinical Lymphoma Myeloma & Leukemia

P575: Gilteritinib Maintenance After Allogeneic Stem Cell Transplantation for Flt3 Mutated Acute Myeloid Leukemia

2023 · Andrius Žučenka, Dominika Vasilevska, et al. · HemaSphere

Works count: 24

Citation count: 24

H-index: 2

I10-index: 1